The invention discloses a
glucan-containing pharmaceutical composition which comprises
glucan-polyethyleneimine and a pharmaceutically
active component activated by cis-
aconitic acid anhydride.
Glucan and polyethyleneimine are bonded through urethane bonds, cis-
aconitic acid anhydride and the pharmaceutically
active component are bonded through
amide bonds, and the pharmaceutically
active component activated by cis-
aconitic acid anhydride and
glucan-polyethyleneimine are bonded through
amide bonds which are jointed between cis-aconitic
acid anhydride and polyethyleneimine. After entering a
human body, the glucan-containing pharmaceutical composition forms a shell-core structure, can not be identified by the reticuloendothelial
system, and gradually concentrates at the site of a tumor
mass. Under the acidic conditions of the
tumor site, the
amide bonds between the pharmaceutically active component activated by cis-aconitic
acid anhydride and polyethyleneimine are broken to release a large amount of the pharmaceutically active component, while the release of the pharmaceutically active component at other sites is extremely low, thus, the
toxicity to the health cells is reduced, and the toxic or
side effect is reduced. The invention discloses a preparation method of the glucan-containing pharmaceutical composition mentioned above.